“…However, as the anthelmintic concentration slowly subsides to sub-lethal concentrations, both homozygousand heterozygous-resistant parasites are able to establish within the host, while homozygous-susceptible parasites still cannot establish, thereby accelerating the development of AHR (Sutherland and Scott, 2010). While several studies have investigated the role of long-acting formulations as a putative risk factor for AHR (Le Jambre et al, 1999;Sutherland et al, 2000;Leathwick et al, 2006;Rendell et al, 2006;Hughes et al, 2007), only two studies were suitable for quantitative data extraction and synthesis (Rendell et al, 2006;Hughes et al, 2007); the pooled estimate showed a marginally significant positive association between the use of long-acting formulations (either as moxidectin or macrocyclic lactone capsules) and AR (Fig. 5).…”